BARCELONA, Jan. 29, 2026 — Ahead Therapeutics, a Spanish biotechnology...
Read More
BARCELONA, Jan. 29, 2026 — Ahead Therapeutics, a Spanish biotechnology...
Read More
Barcelona, 14 August 2025 – Ahead Therapeutics S.L is proud...
Read More
Ahead Therapeutics, a biotech company developing a platform technology to...
Read More
Ahead Therapeutics has been awarded a Public-Private Collaboration (CPP) project...
Read More
BARCELONA, Jan. 29, 2026 — Ahead Therapeutics, a Spanish biotechnology company focused on transformative solutions for autoimmune diseases, today announced it has been awarded a
Barcelona, 14 August 2025 – Ahead Therapeutics S.L is proud to announce that we will be actively participating in two major international scientific events in
Ahead Therapeutics, a biotech company developing a platform technology to induce antigen-specific immune tolerance for the treatment of autoimmune diseases, has received positive feedback from
Ahead Therapeutics has been awarded a Public-Private Collaboration (CPP) project by the Spanish Ministry of Science and Innovation, signifying a major advancement in its mission
Ahead Therapeutics has announced that it has been granted a US patent titled Liposome-based Immunotherapy for its MiMiTOP (Mimicking Tolerogenic Particles). This is a huge
A new study published in the Journal of Autoimmunity reveals the role of macrophages in response to Ahead Therapeutics’ MiMiTOP (Mimicking Tolerogenic Particles) in Type